Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 8/20 | 0.63 |
| ▸ | HTR2B | P41595 | 10/20 | 0.50 |
| ▸ | HTR7 | P34969 | 8/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919828 | 0.89 | SLC9A1 (0.52) | SLC9A1HTR2BHTR7CYP2C9CYP2C19 | |
| SCHEMBL7918849 | 0.81 | HTR2B (0.57) | SLC9A1HTR2BHTR7CYP2C9CYP2C19 | |
| SCHEMBL10148398 | 0.80 | PTPN1 (0.58) | CYP2D6 | |
| SCHEMBL27992224 | 0.77 | SLC9A1 (0.69) | SLC9A1HTR2BHTR7 | |
| SCHEMBL27475392 | 0.77 | SLC9A1 (1.00) | SLC9A1HTR2BHTR7ADRA1DHTR2A | |
| SCHEMBL27705620 | 0.77 | SLC9A1 (0.69) | SLC9A1HTR2BHTR7 | |
| SCHEMBL16502846 | 0.77 | HTR2B (0.57) | SLC9A1HTR2BHTR7CYP2C9CYP2C19 | |
| SCHEMBL3103932 | 0.76 | PLAU (0.40) | SLC9A1SLC6A3 | |
| SCHEMBL30735595 | 0.76 | IKBKB (0.46) | — | |
| SCHEMBL19284588 | 0.76 | IKBKB (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | claimed |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2016-12-29 | — | — | US | claimed |
| EP-1902017-B1 | Antiviral acylguanidine compounds | BIOTRON LTD (AU) | 2014-03-26 | — | — | EP | claimed |
| CN-101208297-B | Antiviral compounds and methods | BIOTRON LTD | 2013-04-24 | — | — | CN | claimed |
| CN-101827589-A | Hepatitis c antiviral compositions and methods | BIOTROM LTD | 2010-09-08 | — | — | CN | claimed |
| EP-2826770-B1 | ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY | BIOTRON LTD (AU) | 2018-09-12 | — | — | EP | disclosed |
| CN-101827589-B | The compositions of anti-hepatitis c virus and method | 拜伊特朗有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-103274970-B | Antiviral compounds and methods | BIOTRON LTD | 2015-02-25 | — | — | CN | disclosed |
| EP-1902017-B1 | Antiviral acylguanidine compounds | BIOTRON LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| CN-101208297-B | Antiviral compounds and methods | BIOTRON LTD | 2013-04-24 | — | — | CN | disclosed |
| CN-101827589-A | Hepatitis c antiviral compositions and methods | BIOTROM LTD | 2010-09-08 | — | — | CN | disclosed |
| CN-101208297-A | Antiviral compounds and methods | BIOTRON LTD (AU) | 2008-06-25 | — | — | CN | disclosed |
| EP-1902017-A1 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006135978-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683263-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | SLC9A1 4116/4885HTR2B 4534/4885HTR7 4247/4885 |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | SLC9A1 4116/4885HTR2B 4534/4885HTR7 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.